DIRS.INFO The most relevant business & tech news

☆ Eli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise Chen
▼ + stars: | 2024-04-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly is a 'multi-diversified drugmaker', says Cantor Fitzgerald's Louise ChenLouise Chen, Cantor Fitzgerald managing director, joins 'Squawk Box' to discuss Eli Lilly's quarterly earnings results, weight loss drug demand, growth outlook, and more.

Persons: Eli Lilly, Cantor Fitzgerald's Louise Chen Louise Chen, Cantor Fitzgerald, Eli

☆ Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street's expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound. Eli Lilly also expects revenue for the year to come in between $42.4 billion and $43.6 billion, an increase of $2 billion at either end of the range. Shares of Eli Lilly jumped almost 8% in premarket trading Tuesday. With a market cap of about $700 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, LSEG, They're Organizations: Analysts, LSEG Locations: San Diego , California, U.S

Eli Lilly — Shares added 5% after Eli Lilly, maker of the Mounjaro diabetes and weight loss drug, beat analysts' expectations for first-quarter adjusted earnings. PayPal — Shares gained 3.6% after the payment company posted $7.70 billion in first-quarter revenue, beating analysts' estimates for $7.51 billion, according to LSEG. The chipmaker posted adjusted earnings of $3.24 per share, higher than the consensus estimate of $3.16 per share, according to LSEG. Earnings of 24 cents per share on $1.37 billion in revenue exceeded consensus forecasts of 11 cents and $1.36 billion, according to FactSet. Adjusted earnings of 71 cents per share topped anticipated earnings of 65 cents per share.

Persons: Eli Lilly —, Eli Lilly, drugmaker, Jefferies, Tesla, Goldman Sachs, Tenet, Corning, FactSet, Sysco, Medifast, Paccar, Bob Bakish, Skydance, Needham, Macheel, Michelle Fox, Yun Li, Lisa Kailai Han, Pia Singh, Sarah Min Organizations: PayPal —, PayPal, Semiconductor, Tenet, FactSet, Technology, GE Healthcare Technologies, LSEG, Taco Bell, KFC, Paramount Global, CBS, Paramount Locations: Indianapolis, China, LSEG, FactSet, Houston

☆ Jim Cramer says GE Healthcare's unwarranted post-earnings plunge is a buying opportunity
▼ + stars: | 2024-04-30 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +5 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Jim Cramer has said repeatedly the Fed does not need to cut anytime soon. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

Persons: Jim Cramer, Jerome Powell, Jim, Eli Lilly, Eaton, Lilly, We're, McDonald, —, Jeff Marks, Jim Cramer's Organizations: CNBC, Dow Jones, Nasdaq, Federal, Fed, GE Healthcare, Constellation Brands, Molson Coors, TAP, Modelo, Corona, Web Services, Microsoft, Starbucks, Jim Cramer's Charitable Locations: China, Will

☆ U.S. Lags Behind Other Countries in Hepatitis-C Treatment
▼ + stars: | 2024-04-28 | by ( Ted Alcorn | ) www.nytimes.com time to read: 1 min

In the 10 years since the drugmaker Gilead debuted a revolutionary treatment for hepatitis C, a wave of new therapies have been used to cure millions of people around the world of the blood-borne virus. Today, 15 countries, including Egypt, Canada and Australia, are on track to eliminate hepatitis C during this decade, according to the Center for Disease Analysis Foundation, a nonprofit. Each has pursued a dogged national screening and treatment campaign. Spread through the blood including IV drug use, hepatitis C causes liver inflammation, though people may not display symptoms for years. Only a fraction of Americans with the virus are aware of the infection, even as many develop the fatal disease.

Organizations: Center, Disease Analysis Locations: Egypt, Canada, Australia, United States

☆ Jim Cramer's quick thoughts on 5 stocks: Chevron, Snap, Intel, AbbVie and Colgate
▼ + stars: | 2024-04-26 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +1 min

Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. "I've been itching to buy Devon " again for the CNBC Investing Club portfolio . Snap : The social media company reported a much better-than-expected quarter with higher revenue and active users. Colgate-Palmolive : The consumer products giant had a strong quarter with organic sales up 9.8% and a full-year sales guidance raise. I admit that," Cramer said, referring to Procter & Gamble , which is a stock owned by the Investing Club.

Persons: Jim Cramer's, Jim Cramer, Cramer, Chevron, Botox, Colgate, — Organizations: CNBC, Club, Chevron, Intel, Colgate, Palmolive, Procter, Procter & Gamble, Investing Locations: Devon

☆ Jim Cramer shares his thoughts on Caterpillar, Dow, Chipotle, Merck and ServiceNow
▼ + stars: | 2024-04-25 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

Shares fell more than 7%. Dow Inc : Shares fell more than 1.5% despite the chemicals maker reporting better-than-expected results. I'd buy the stock," Cramer said. Chipotle : The burrito chain reported better-than-expected sales and earnings, with same-store sales growth of 7% easily surpassing Wall Street estimates. ServiceNow : Shares fell more than 6% despite the maker of workflow software's quarterly results beating on the top-and-bottom lines.

Persons: Jim Cramer's, Jim Cramer, I'd, Cramer, Bill McDermott Organizations: CNBC, Club, Caterpillar, Dow Inc, Wall, Merck Locations: Dover

☆ Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
▼ + stars: | 2024-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Bristol Myers Squibb on Thursday reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and several new drugs posted sales growth. Two-thirds of savings are associated with drug research and development, Bristol Myers Squibb executives said during an earnings call on Thursday. Those deals come as Bristol Myers faces pressure to launch new drugs and offset the potential loss of revenue from top-selling treatments. Shares of Bristol Myers fell more than 1% in premarket trading Tuesday.

Persons: Bristol Myers, Samit Hirawat, Chris Boerner, Boerner, Revlimid Organizations: Bristol Myers Squibb, Bristol Myers, Karuna Therapeutics, SystImmune, Bristol, LSEG Locations: Cambridge, Cambridge , Massachusetts, Here's

☆ Stocks making the biggest moves midday: Tesla, Hilton, Boeing, Mattel and more
▼ + stars: | 2024-04-24 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +4 min

Hilton Worldwide Holdings — The hotel stock climbed 4% on the back of strong first-quarter adjusted earnings and raised full-year guidance. Mattel saw $810 million in revenue during the quarterly period, which was less than the consensus estimate of $832 million. Adjusted earnings per share came in at 61 cents, beating analysts' expectations of 27 cents per share, according to LSEG. Revenue of $757 million was greater than the $739 million analysts anticipated. Sales of Biogen's Alzheimer's drug Leqembi came in at about $19 million for the quarter, surpassing the $11 million analysts had anticipated, per FactSet.

Persons: LSEG, Elon Musk, Tesla, Musk's, Hilton, Mattel, Enphase, Biogen, LSEG ., Leqembi, —, Jesse Pound, Alex Harring, Michelle Fox, Lisa Han Organizations: Boeing, . Old Dominion, Hilton Worldwide Holdings, Texas, Mattel, LSEG, Hasbro, Enphase Energy, Dynamics —, Dynamics, Seagate Technology, Seagate Locations: FactSet, LSEG

☆ Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
▼ + stars: | 2024-04-24 | by ( Ryan Anastasio | ) www.cnbc.com time to read: +2 min

The U.S. Senate has launched an investigation into the high price of Novo Nordisk 's popular weight loss and diabetes drugs Ozempic and Wegovy in the United States. "As important as these drugs are, they will not do any good for the millions of patients who cannot afford them," wrote Sanders. Wegovy, which is even more expensive than Ozempic, is subject to similarly disparate pricing overseas, wrote Sanders. The powerful progressive senator also made a simple request of the drug company CEO: "Will Novo Nordisk substantially reduce both the list price and the net price of both Ozempic and Wegovy?" He gave Novo Nordisk until May 8 to answer a series of questions about the drug's pricing.

Persons: Ozempic, Danish drugmaker, Sen, Bernie Sanders, Sanders, Lars Fruergaard Jørgensen, Jørgensen Organizations: U.S . Senate, Novo Nordisk, Vermont Independent, Health, Education, Labor, Pensions, Nordisk Locations: United States, Danish, Vermont, Canada, Germany

☆ Novartis lifts guidance after first-quarter results beat expectations
▼ + stars: | 2024-04-23 | by ( ) www.cnbc.com time to read: +2 min

Signage is displayed on the exterior of the Novartis AG Institutes for BioMedical Research building in Cambridge, Massachusetts, U.S., on Friday, Aug. 5, 2016. Swiss drugmaker Novartis on Tuesday raised its full-year guidance after reporting better-than-expected first-quarter results. In a statement, it said 2024 net sales would likely grow by a high-single to low double-digit percentage with adjusted operating income expected to grow by a low double-digit to mid-teens percentage. It has previously predicted that adjusted operating income would increase by a "high single-digit" percentage with "mid single-digit" sales growth. Quarterly adjusted operating income gained 16% to $4.54 billion, beating an average analyst estimate of about $4.3 billion.

Persons: Bristol Myers, Giovanni Caforio, Joerg Reinhardt, Vas Narasimhan, Sandoz Organizations: Novartis, Institutes, Research, Bristol, Bristol Myers Squibb Locations: Cambridge , Massachusetts, U.S

☆ Stocks making the biggest moves midday: Spotify, JetBlue, Danaher, General Motors and more
▼ + stars: | 2024-04-23 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

General Motors — Shares rose more than 4% after the automaker exceeded analysts' expectations for its first-quarter results . General Motors posted adjusted earnings of $2.62 per share on revenue of $43.01 billion. Danaher — The life sciences firm popped more than 7% after beating analysts' expectations for its first-quarter results. Spotify — The streaming music company surged 16% after easily topping earnings expectations . KeyBanc Capital Markets downgraded Sunnova Energy to sector weight from overweight, citing caution on residential solar names particularly ahead of first-quarter earnings.

Persons: General Motors, JetBlue's, LSEG, Nucor, Danaher, Sherwin, Williams, Sunnova, LKQ, MSCI, — CNBC's Michelle Fox, Sarah Min, Jesse Pound Organizations: General Motors, General, GE Aerospace —, GE, PepsiCo, Novartis, JetBlue Airways —, Spotify, JPMorgan, Sunnova Energy, KeyBanc, FactSet Locations: U.S, LSEG . Cleveland, Cleveland

☆ Jim Cramer shares his thoughts on RTX, Pepsi, Nucor, Novartis and Cadence Design Systems
▼ + stars: | 2024-04-23 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +1 min

RTX : Shares were roughly flat after the aerospace and defense company delivered a quarterly earnings beat and reaffirmed its full-year 2024 outlook for sales, adjusted earnings and free cash flow. He goes out on an absolute high," Jim Cramer said, noting the strength in its Pratt & Whitney division. Nucor : The steelmaker's first-quarter earnings and sales came in lighter than expected, and its current-quarter outlook disappointed, as well. Cramer noted Nucor CEO Leon Topalian is set to appear on "Mad Money" later Tuesday, and he'll be seeking clarity around the impact pricing has had on the company. Cadence Design Systems : The semiconductor design software maker's second-quarter guidance came in light, saying customers are delaying orders due to hardware transition.

Persons: Jim Cramer's, Greg Hayes, Jim Cramer, Cramer, Leon Topalian, he'll, I've, Vas Organizations: CNBC, Club, Pratt & Whitney, PepsiCo, Novartis, Cadence Design Systems Locations: U.S, Swiss

☆ Drugmaker Novartis climbs 4.4% after guidance rise on sales of blockbuster drugs
▼ + stars: | 2024-04-23 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Signage for Novartis AG at a building in the company's headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023. Shares of Swiss drugmaker Novartis climbed as much as 4.8% in early deals on Tuesday, after the company raised its full-year guidance following better-than-expected first-quarter results. Novartis' net sales rose 11% in the first three months of the year, while core operating income increased 22% over the same period. Narasimhan said the company continued to advance its drug pipeline in the first quarter, including treatments for prostate cancer and leukemia. "The momentum in our business and pipeline gives us continued confidence in our mid- and long-term growth outlook," he said.

Persons: Vas Narasimhan, Narasimhan Organizations: Novartis AG, Swiss, Novartis Locations: company's, Basel, Switzerland, London

☆ Stocks making the biggest premarket moves: General Motors, GE Aerospace, Novartis, JetBlue and more
▼ + stars: | 2024-04-23 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

The results were better than analysts' expectations of 65 cents per share on revenues of $15.14 billion, according to LSEG. UPS posted $1.43 adjusted earnings per share while analysts had estimated $1.29 earnings per share, according to LSEG. Danaher — The life sciences firm popped more than 8% after beating analysts expectations for its first-quarter results. Spotify — Shares rallied 8.4% after the music streaming company's first-quarter revenues beat analysts' expectations. Sherwin-Williams reported adjusted earnings per share of $2.17, missing the FactSet consensus estimate of $2.22.

Persons: General Motors, Nucor, Danaher, Lockheed Martin, LSEG, Sherwin, Williams, — Hakyung Kim, Tanaya Macheel, Alex Harring, Jesse Pound, Lisa Han Organizations: General, GM, GE Aerospace —, United Parcel Service, UPS, Pepsico —, Pepsico, Novartis — U.S, JetBlue Airways —, JetBlue, Wall Street, SAP — U.S, SAP, Revenue, Lockheed, —, Spotify Locations: Swiss, Wall Street Cleveland

Lars Fruergaard Jorgensen has a problem: Too many people want what he’s selling. Even if the company isn’t quite a household name, the TV jingle for its best-selling drug — “Oh-oh-ohhh, Ozempic!” — might ring in your ears. Across the United States, Novo Nordisk’s diabetes and weight-loss drugs, Ozempic and Wegovy, have soared to celebrity status and helped make the company Europe’s most valuable public firm. Last year, when the company was celebrating its centenary, Novo Nordisk’s revenue jumped by a third, to 232 billion Danish kroner, or $33 billion. “Nobody forecast a 100-year-old company would grow more than 30 percent,” he said, seemingly torn between pride and amazement.

Persons: Lars Fruergaard Jorgensen, Jorgensen, ” Mr, ”, Wegovy Organizations: Novo Nordisk, Novo Nordisk’s, Nordisk Locations: Danish, United States, Copenhagen

☆ Millions of Girls in Africa Will Miss HPV Shots After Merck Production Problem
▼ + stars: | 2024-04-18 | by ( Stephanie Nolen | ) www.nytimes.com time to read: +1 min

Nearly 1.5 million teenage girls in some of the world’s poorest countries will miss the chance to be protected from cervical cancer because the drugmaker Merck has said it will not be able to deliver millions of promised doses of the HPV vaccine this year. Merck has notified Gavi, the international organization that helps low- and middle-income countries deliver lifesaving immunizations, and UNICEF, which procures the vaccines, that it will deliver only 18.8 million of the 29.6 million doses it was contracted to deliver in 2024, Gavi said. That means that more than 10 million girls will not receive their expected HPV shots this year — and 1.5 million of them most likely will never get them because they will be too old to qualify for the vaccine in subsequent years. Patrick Ryan, a spokesman for Merck, said the company “experienced a manufacturing disruption” that required it to hold and reinspect many doses by hand. He declined to give further details about the cause of the delay.

Persons: Merck, Gavi, Patrick Ryan Organizations: Merck, UNICEF

☆ Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker says
▼ + stars: | 2024-04-17 | by ( Jen Christensen | ) edition.cnn.com time to read: +4 min

CNN —Zepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said Wednesday. Based on results from trials in people with sleep apnea, the company said it plans to submit the material to the US Food and Drug Administration to potentially expand the use of Zepbound for obstructive sleep apnea. Obstructive sleep apnea is a disorder that causes people to briefly stop breathing while they are sleeping, sometimes several times an hour. While people are more at risk for obstructive sleep apnea as they get older, it often develops when people gain weight and have overweight or obesity. Some doctors have been prescribing the weekly injection off label to people with obstructive sleep apnea, and Lilly has been testing the drug for obstructive sleep apnea since June 2022.

Persons: CNN —, Eli Lilly, Lilly, didn’t, Dr, Sanjay Gupta, CNN’s Meg Tirrell, Amanda Sealy Organizations: CNN, Food and Drug Administration, World Health, US Food and Drug Administration, CNN Health, American Diabetes Association

☆ Another perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too
▼ + stars: | 2024-04-17 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +4 min

GLP-1 drugs were originally developed to treat type 2 diabetes. Drugmakers are discovering the injections may also aid weight loss, heart issues, and sleep apnea. AdvertisementAnother new indication for injectable GLP-1 drugs: better sleep. On Wednesday, drugmaker Eli Lilly announced positive results from a large, phase-3 clinical trial, testing Zepbound (the drug name for tirzepatide) as a treatment for sleep apnea. Related storyAlready, GLP-1 drugs have been indicated for the treatment of:ObesityHeart diseaseAdvertisementIn clinical trials, GLP-1 drugs have also shown some promise for treating other conditions, including:Non-alcoholic fatty liver diseaseAddictionDepressionParkinson's and Alzheimer'sCancerThese breakthroughs may be tied to the gut-brain connectionScientists think that the main reason GLP-1 drugs work well is because of their effect on our body's gut-brain connection.

Persons: —, drugmaker Eli Lilly, Eli Lilly, KATERYNA, Daniel Drucker, GLP, Eric Topol Organizations: Service, Food and Drug Administration, American Diabetes Association, University of Toronto

☆ Stocks making the biggest moves midday: UnitedHealth, SolarEdge, Bank of America, Tesla and more
▼ + stars: | 2024-04-16 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

UnitedHealth posted better-than-expected first-quarter revenue and reaffirmed its full-year earnings forecast of $27.50 to $28 per share excluding items. Johnson & Johnson — The drugmaker slipped 2% despite beating first-quarter profit estimates and reporting in-line revenue. Johnson & Johnson adjusted its full-year sales forecast for 2024 to a range of $88 billion to $88.4 billion compared to a previous forecast of $87.8 billion to $88.6 billion. The firm also surpassed analysts' earnings and revenue estimates. Bank of America — Charlotte-based Bank of America fell 3.5% after quarterly profit tumbled 18% to $6.67 billion , or 76 cents a share.

Persons: UnitedHealth, Johnson, Morgan Stanley —, Tesla, —, Sarah Min, Tanaya Macheel Organizations: Dow Jones, FactSet, Johnson, Technologies, Barclays, Live, Entertainment, Journal, U.S . Department of Justice, Bank of America, of America, Revenue

☆ Stocks give up early gains — Here's why a busy week of earnings is good news for investors
▼ + stars: | 2024-04-15 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. There is nothing markets hate more than uncertainty, which is why stocks struggled to hold onto their early gains. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Morgan Stanley, Goldman Sachs, Charles Schwab bode, Eli Lilly, It's, Jim Cramer's, Jim Organizations: CNBC, Dow Jones, Abbott Laboratories, Jim Cramer's Charitable Locations: East

☆ Eli Lilly's top-selling drug last year is softening. But it may not matter for the stock
▼ + stars: | 2024-04-12 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. JPMorgan flagged similar trends for Trulicity, which led all Lilly drugs with $7.13 billion in sales for all of 2023. The thesis is predicated on Eli Lilly growing faster than the broader pharmaceutical industry for years to come. Over the past three years, shares of Eli Lilly have soared nearly 300%, compared with a 24% gain for the S & P 500 . A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.

Persons: Eli Lilly, Wells, Lilly, Mounjaro, Jim Cramer, tirzepatide, Zepbound, Eli Lilly's, Novo, Wegovy, drugmaker, Jim Cramer's, Jim, Eli Lilly Pharmaceutical, George Frey Organizations: Wall Street, JPMorgan, Club, Novo Nordisk, Novo, BMO Capital Markets, Drug Administration, FDA, The Club, CNBC Locations: Wells Fargo, Trulicity, Tirzepatide, Danish, Lilly, Provo , Utah

☆ Morgan Stanley tumbles, GE Healthcare climbs — what's driving Thursday's major portfolio stock moves
▼ + stars: | 2024-04-11 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

Persons: Jim Cramer, Stocks, Banks, JPMorgan Chase, Jamie Dimon, Morgan Stanley, Bausch, Jim, Jim Cramer's Organizations: CNBC, Club, Citigroup, JPMorgan, Securities and Exchange Commission, U.S, Appeals, Federal Circuit, Health, Jefferies, Xifaxan, Bausch Health, Costco, GE Healthcare, Mizuho, Broadcom, Apple, Nvidia, Jim Cramer's Charitable Locations: Wells Fargo, BlackRock

☆ Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial
▼ + stars: | 2024-04-04 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson's disease, too. But more research is needed to determine whether newer iterations of GLP-1s from Novo Nordisk and Eli Lilly may also help Parkinson's patients. The trial followed 156 people with early Parkinson's disease for a year. But one group was given an additional daily injection of Sanofi's drug, while the other was given a placebo. But use of Sanofi's drug was associated with an increased risk of gastrointestinal side effects, which are common across all GLP-1s.

Persons: Eli Lilly, Sanofi, drugmaker Organizations: Sanofi, Novo Nordisk, The New England, French Ministry of Health, Prevention, CNBC Locations: Novo, France, The

☆ CNN Exclusive: Adderall prescriptions have been filled less often amid ongoing shortage in the US
▼ + stars: | 2024-04-02 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +10 min

CNN —About 1 in every 10 people in the US who uses Adderall or similar combination drugs to treat attention-deficit/hyperactivity disorder (ADHD) has been affected by an ongoing shortage, a new analysis suggests. The US Food and Drug Administration announced that Adderall was in shortage in mid-October 2022, and the share of people with ADHD who filled their prescriptions for Adderall and related medications plunged in the following months. Patients were considered eligible for a monthly prescription fill if they had filled one within the previous two years. Prescriptions for medications used to treat ADHD surged during the Covid-19 pandemic, especially among young adults and women, one study found. But it’s been about a year and a half since she’s been able to fill her Adderall prescription in a “totally uneventful” way, she said.

Persons: Adderall, Robert Califf, Anne Milgram, David Goodman, ”, Mary Beth King, it’s, she’s, ” King, King, ” Goodman, John Mitchell, ” Mitchell, they’re, ’ ”, –, “, Dr, Sanjay Gupta, hasn’t Organizations: CNN, US Food and Drug Administration, Drug, of Psychiatry, Behavioral Sciences, Johns Hopkins School of Medicine, American Professional Society, New, Psychiatric Institute, Columbia University Irving Medical Center, Duke University School of Medicine, Get CNN, CNN Health Locations: Sweden

Search resuls for: "Drugmaker"

25 mentions found